<DOC>
	<DOCNO>NCT03038399</DOCNO>
	<brief_summary>This long-term extension study open-label , multiple‑dose study evaluate long‑term safety , tolerability , efficacy PD vamorolone administer daily liquid oral suspension Treatment Period 24 month young boy DMD participate VBP15‑002 Phase IIa VBP15-003 Phase IIa extension core study .</brief_summary>
	<brief_title>Long-term Extension Study Assess Vamorolone Boys With Duchenne Muscular Dystrophy ( DMD )</brief_title>
	<detailed_description>This study evaluate safe use new medication call vamorolone two week child DMD , boys DMD take study medication improve muscle function compare boy DMD study take type steroid , see boys DMD take study medication gain less weight compare boy DMD prior study take another type steroid call prednisone . Enrolled participant take study medication 24 month .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>1 . Subject 's parent legal guardian provide write informed consent HIPAA authorization ( applicable ) prior VBP15LTE longterm extension studyspecific procedure ; 2 . Subject previously complete study VBP15003 include Week 24 Final assessment , prior enrol VBP15LTE study conclusion VBP15003 Week 24 Visit [ Note : enter dosetapering period , subject enrol within 8 week VBP15‑003 final visit follow dose‑tapering ] ; 3 . Subject parent/guardian willing able comply schedule visit , study drug administration plan , study procedure . 1 . Subject serious severe adverse event study VBP15003 , opinion Investigator , probably definitely related vamorolone use precludes safe use vamorolone subject longterm extension study ; 2 . Subject current history major renal hepatic impairment , diabetes mellitus immunosuppression ; 3 . Subject current history chronic systemic fungal viral infection ; 4 . Subject use mineralocorticoid receptor agent , spironolactone , eplerenone , canrenone ( canrenoate potassium ) , prorenone ( prorenoate potassium ) , mexrenone ( mexrenoate potassium ) within 4 week prior first dose study medication ; 5 . Subject evidence symptomatic cardiomyopathy . [ Note : Asymptomatic cardiac abnormality investigation would exclusionary ] ; 6 . Subject currently treat receive previous treatment oral glucocorticoid immunosuppressive agent [ Notes : Past transient use oral glucocorticoid oral immunosuppressive agent longer 3 month cumulative , last use least 3 month prior first dose study medication , consider eligibility casebycase basis . Inhaled and/or topical glucocorticoid prescribe indication DMD permit must administer stable dose least 3 month prior study drug administration ] ; 7 . Subject use idebenone within 4 week prior first dose study medication ; 8 . Subject allergy hypersensitivity study medication constituent ; 9 . Subject severe behavioral cognitive problem preclude participation study , opinion Investigator ; 10 . Subject previous ongoing medical condition , medical history , physical finding laboratory abnormality could affect safety , make unlikely treatment followup correctly complete impair assessment study result , opinion Investigator 11 . Subject currently take investigational drug , take investigational drug vamorolone within 3 month prior start study treatment . Note : Subjects may reevaluate ineligible due transient condition would prevent subject participating .</criteria>
	<gender>Male</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>vamorolone</keyword>
</DOC>